Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 4.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 March 2024) | Viewed by 11184
Special Issue Editors
Interests: thioredoxin reductase; cytotoxicity; anticancer agents; drug resistance
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal inorganic chemistry; organometallic chemistry; metal-based complexes; antitumor platinum drugs; drug delivery of antitumor drugs by inorganic nanocarriers
Special Issues, Collections and Topics in MDPI journals
Interests: medicinal inorganic chemistry; organometallic chemistry; metal-based complexes; antitumor platinum drugs; drug delivery of antitumor drugs by inorganic nanocarriers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Due to the great success of the first, second and third edition of “Cisplatin in Cancer Therapy: Molecular Mechanisms of Action”, in which approximately 20, 7 and 9 papers, respectively, were published (and which can be accessed at https://www.mdpi.com/journal/ijms/special_issues/cisplatin_cancer_therapy), a fourth edition of this Special Issue has been launched.
Although it has been 45 years since the FDA approval of cisplatin for the treatment of cancer, its mechanism of action has not yet been fully elucidated. The mechanism of action of cisplatin is known so far to include four key steps: (1) cellular uptake, (2) activation by aquation, (3) DNA binding, and (4) the processing of DNA lesions, which may alter both DNA transcription and RNA replication, leading to cancer cell death. Evidence correlating the pharmacological effect of cisplatin with its capability to damage the structure of DNA is irrefutable, but the intimate connections between the causes and the effects (especially as related to step 4) have not been fully demonstrated. Despite this deficiency, 50% of all cancer chemotherapeutic treatments include a platinum drug, either cisplatin or carboplatin and oxaliplatin. Complete elucidation of the mechanism of action of platinum-based drugs is a fundamental and high-priority task that could potentially allow the amelioration or elimination of the severe side effects accompanying patient treatment. Another important challenge is to explore in detail the nature of the intracellular pathways affected by the platinum–DNA adducts, which are responsible for developing resistance or a differential response in tumors to platinum drugs (i.e., cisplatin and oxaliplatin have different activities toward colorectal cancer). The study of the molecular determinants involved in the mechanism of action of cisplatin and its analogs is an extremely important interdisciplinary field that requires the collaboration of chemists, biologists, pharmacologists, and physicians, who, in some cases, do not always communicate on the same level. While the stakes are high, we are confident that these uncertainties regarding the mechanism of action of cisplatin can be elucidated within five years, in time to celebrate the 50th anniversary of the FDA’s approval of cisplatin.
Dr. Valentina Gandin
Dr. James D. Hoeschele
Dr. Nicola Margiotta
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cisplatin
- antitumor platinum agents
- alkylating drugs
- platinum–DNA adducts
- DNA–repair
- mechanisms
- apoptosis
- carboplatin
- oxaliplatin
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.